Immunomodulacyjne leczenie śródmiąższowej choroby płuc związanej z wariantami genu surfaktantu (TIPS)
Immunomodulacyjne leczenie śródmiąższowej choroby płuc związanej z wariantami genów surfaktantu
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.
Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.
The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.
Main objective and primary endpoint : Main objective:
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.
Primary endpoint:
Difference in forced vital capacity decline between the 2 groups at one year.
Secondary objectives and endpoints : Secondary objectives:
- tolerance of the triple therapy,
- correlation between the respiratory, radiological and clinical functional response,
- quality of life of the patients,
- overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival
Secondary endpoints:
- Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
- Thoracic CT scan and PFT at 6 months and one year after randomization
- Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
- Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care
Category : Category 2
Population of study participants: Patients aged over 18 years with ILD and SRG variant
Number of participants included : 30
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Annabelle METOIS
- Numer telefonu: 0140257939
- E-mail: annabelle/metois@aphp.fr
Kopia zapasowa kontaktu do badania
- Nazwa: BORIE Raphaël
- E-mail: raphael.borie@aphp.fr
Lokalizacje studiów
-
-
-
Bron, Francja, 69500
- Pneumologie Louis Pradel
-
Kontakt:
- COTTIN Vincent
- E-mail: vincent.cottin@chu-lyon.fr
-
Lille, Francja, 59037
- Pneumologie Institu Coeur Poumon
-
Kontakt:
- WEMEAU Lidwine
- E-mail: lidwibne.wemeau@chru-lille.fr
-
Rennes, Francja, 35033
- Pneumologie Pontchaillou
-
Kontakt:
- JOUNEAU Stéphane
- E-mail: stephane.jouneau@chu-rennes.fr
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age ≥ 18 years and <80 years
- Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
- ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years
Exclusion Criteria:
- Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
- Pregnancy and breastfeeding
- Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
- Desire to have a child within 22 months
- Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
- Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
- No affiliation to any health insurance system
- Refusal to participate to the study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3
The experimental treatment will be the combination of:
|
Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no |
|
Aktywny komparator: Standard of care
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Difference in forced vital capacity decline between the 2 groups at one year.
Ramy czasowe: 12 Months
|
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene. |
12 Months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
tolerance of the triple therapy
Ramy czasowe: 12 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization) |
12 months
|
|
correlation between the respiratory, radiological and clinical functional response,
Ramy czasowe: 12 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization |
12 months
|
|
Quality of life of the patients
Ramy czasowe: 12 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization, |
12 months
|
|
tolerance of the triple therapy
Ramy czasowe: 6 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
6 months
|
|
tolerance of the triple therapy
Ramy czasowe: 3 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
3 months
|
|
correlation between the respiratory, radiological and clinical functional response,
Ramy czasowe: 6 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization |
6 months
|
|
Quality of life of the patients
Ramy czasowe: 9 months
|
Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization, |
9 months
|
|
Quality of life of the patients
Ramy czasowe: 6 months
|
Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization, |
6 months
|
|
Quality of life of the patients
Ramy czasowe: 3 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization, |
3 months
|
|
Overall survival
Ramy czasowe: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Transplant-free survival
Ramy czasowe: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Exacerbation free-survival
Ramy czasowe: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Hospitalization-free survival
Ramy czasowe: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
tolerance of the triple therapy
Ramy czasowe: 9 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), |
9 months
|
|
tolerance of the triple therapy
Ramy czasowe: 12 months
|
ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients) |
12 months
|
|
tolerance of the triple therapy
Ramy czasowe: 12 months
|
Ophthalmological (at one year after randomization) |
12 months
|
|
tolerance of the triple therapy
Ramy czasowe: 9 months
|
ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients) |
9 months
|
|
tolerance of the triple therapy
Ramy czasowe: 6 months
|
ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients) |
6 months
|
|
tolerance of the triple therapy
Ramy czasowe: 3 months
|
ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) |
3 months
|
|
Overall survival
Ramy czasowe: 9 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization |
9 months
|
|
Overall survival
Ramy czasowe: 6 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization |
6 months
|
|
Overall survival
Ramy czasowe: 3 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization |
3 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Układu Oddechowego
- Choroby płuc
- Choroby płuc, śródmiąższowe
- Organiczne chemikalia
- Związki heterocykliczne
- Związki heterocykliczne, 2-ring
- Związki heterocykliczne, sterowanie stopieniem
- Związki policykliczne
- Ciąży
- Ciężarne
- Steroidy
- Związki sterownika
- Macrolides
- Laktony
- Ciąży
- Quinoliny
- Aminoquinolines
- Erytromycyna
- Poliketidy
- Chlorochina
- Prednizon
- Hydroksychlorochina
- Azytromycyna
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- APHP251230
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .